Strata Critical Medical (SRTA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.12
- Estimate
- -$0.02
- Surprise
- -500.0%
- Revenue (period 2026-06-30)
- $72.5M
- Score today
- 6.6/10
Revenue source: xbrl.
How the report landed
Strata Critical Medical (SRTA) reported a wider loss than forecast — diluted EPS of -$0.12 against the -$0.02 estimate (a 500.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SRTA Sell at 6.6/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -500.0% surprise compares with a -322.0% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Quality below floor (3.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.22
- Price target
- $8.13
- Stop
- $4.95
- Upside to target
- +55.7%
- Reward-to-risk
- 6.7:1
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
SRTA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $468.0M
- 52-week range
- $3.95–$6.50
- Off 52-week high
- 19.7%
- RSI (14)
- 20
- Volume vs avg
- 0.62×
- Score today
- 6.6/10